Phytol is an acyclic diterpene alcohol derived from chlorophyll metabolism and appears across plant, algal, and seed-oil systems, including davana in the AromaForge archive. Compared with many trace aroma constituents, phytol has a relatively large preclinical literature covering inflammatory signaling, oxidative stress, immune modulation, and other mechanistic endpoints. That said, the evidence still leans heavily on cell and animal models, and an important inhalation-safety paper argues against using phytol as a vaping excipient.
Chemical identity and composition
PubChem resolves phytol to CID 5280435 with formula C20H40O and the natural chiral E-isomer naming pattern. ChEBI describes it as a diterpenoid and long-chain primary fatty alcohol with roles as a plant and algal metabolite. In the local archive, davana oil includes phytol at 2.1%, which fits its broader profile as a recurring but usually non-dominant oxygenated diterpene marker in plant-derived aromatic materials.
Aroma and practical use
- Use the recorded green, balsamic, soft, waxy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2014 mouse study reported that phytol reduced carrageenan-induced paw edema, leukocyte and neutrophil recruitment, MPO activity, TNF-alpha, IL-1beta, and malondialdehyde while increasing glutathione levels.
This is one of the clearer direct isolated-phytol anti-inflammatory studies located in this pass.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 preclinical assessment reported dose-dependent anti-inflammatory activity for phytol and proposed COX-1, COX-2, NF-kappaB, and IL-1beta dependent pathways from combined assay and in silico data.
The paper broadens mechanistic interpretation, but it remains preclinical.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2022 human-cell study found that phytol from hemp seed oil shifted monocyte-macrophage plasticity toward anti-inflammatory phenotypes and reduced IL-1beta, IL-6, and TNF-alpha in LPS-treated macrophages.
This is a stronger-than-average human-cell mechanism source, but not a human clinical study.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 inhalation toxicology study in Sprague-Dawley rats reported severe clinical signs, pulmonary tissue injury, and no established safe exposure range for phytol as a vaping-product excipient.
This is the most important safety-specific source located in this pass for concentrated inhalation exposure.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · Fragrance material review on phytol, Food Chem Toxicol (Api et al., Regul Toxicol Pharmacol supplement 2009), citing IFRA 2007 survey-reported average maximum use level of 0.20% in fine fragranceThe 2021 rat inhalation study found severe pulmonary injury with phytol exposure and concluded that phytol use as a vaping excipient is not recommended.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Much of phytol's benefit-facing literature is preclinical, so consumer-facing copy should avoid implying established human anti-inflammatory or immune benefits.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A constituent-specific topical safety limit or fragrance-standard restriction for isolated phytol was not verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
reduced_cytokine_and_neutrophil_signaling
Animal and cell studies describe phytol-associated reductions in IL-1beta, TNF-alpha, MPO activity, neutrophil migration, and oxidative stress markers during induced inflammation models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
interaction_with_cox_nfkb_and_il1b_pathways
A 2020 preclinical assessment proposed COX-1, COX-2, NF-kappaB, and IL-1beta dependent pathways as plausible anti-inflammatory targets for phytol based on combined in vivo, in vitro, and computational work.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
macrophage_reprogramming_toward_less_inflammatory_states
A 2022 Foods paper reported that phytol shifted human monocytes and macrophages toward non-classical or M2-like phenotypes while reducing LPS-induced IL-1beta, IL-6, and TNF-alpha production.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (4)
- No isolated-phytol human clinical efficacy trial was verified in this pass.
- The strongest safety signal located here concerns inhalation exposure in vaping-style use, not ordinary trace aromatic exposure.
- The verified numeric dermal figure is a 2007 IFRA survey-reported average maximum fine-fragrance use level rather than a modern QRA-derived sensitization limit.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.